Adamas to Present at Upcoming William Blair Conference
June 03 2020 - 4:01PM
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to
developing and delivering medicines that make a clinically
meaningful difference to people affected by neurological diseases,
today announced that Neil F. McFarlane, the Company’s Chief
Executive Officer, is scheduled to present at the William Blair
Growth Stock Conference on Wednesday, June 10 at 9:20 a.m. Central
Time (7:20 a.m. Pacific Time).
The presentation will be webcast live from the
investor relations section of the Adamas website at
http://ir.adamaspharma.com/events-presentations. An archived
version of the webcast will be available via replay for 30 days
following the presentation.
About Adamas Pharmaceuticals,
Inc.At Adamas, our purpose and vision are clear: deliver
innovative medicines that make a clinically meaningful difference
for patients, caregivers and society. We are a fully-integrated
company focused on growing a portfolio of therapies to address a
range of neurological diseases. In 2018, Adamas successfully
launched GOCOVRI® (amantadine) extended-release capsules, the first
and only FDA-approved medicine for the treatment of dyskinesia in
patients with Parkinson’s disease receiving levodopa-based therapy,
with or without concomitant dopaminergic medications. GOCOVRI is
also the only medicine clinically proven to reduce both dyskinesia
and OFF. For more information, please visit
www.adamaspharma.com.
Contact:Investors: Peter
VozzoManaging Director,
Westwicke443-213-0505peter.vozzo@westwicke.com
Media: Sarah MathiesonVice President of
Corporate Communications510-450-3528smathieson@adamaspharma.com
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From May 2024 to Jun 2024
Adamas Pharmaceuticals (NASDAQ:ADMS)
Historical Stock Chart
From Jun 2023 to Jun 2024